Research programme: recombinant protein therapeutics - Primrose Bio
Alternative Names: PF 91XLatest Information Update: 28 May 2024
At a glance
- Originator Pfenex
- Developer Primrose Bio
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Unspecified in USA (Parenteral)
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
- 01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals